Equities Analysts Set Expectations for COGT FY2026 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Wedbush boosted their FY2026 EPS estimates for shares of Cogent Biosciences in a report issued on Monday, June 30th. Wedbush analyst D. Nierengarten now expects that the technology company will earn ($1.12) per share for the year, up from their prior estimate of ($1.13). Wedbush has a "Neutral" rating and a $10.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences' FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.23) EPS.

A number of other equities research analysts also recently commented on the company. Needham & Company LLC reaffirmed a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. JPMorgan Chase & Co. raised their price target on shares of Cogent Biosciences from $21.00 to $25.00 and gave the stock an "overweight" rating in a research report on Thursday, May 29th. Robert W. Baird dropped their price objective on shares of Cogent Biosciences from $8.00 to $7.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright cut their price objective on shares of Cogent Biosciences from $14.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 20th. Three investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Cogent Biosciences has a consensus rating of "Moderate Buy" and a consensus target price of $14.43.

Cogent Biosciences Price Performance

Cogent Biosciences stock traded up $0.21 during trading hours on Thursday, hitting $7.62. 1,862,978 shares of the stock traded hands, compared to its average volume of 1,348,265. The firm's 50 day moving average price is $6.04 and its 200-day moving average price is $6.74. The stock has a market capitalization of $867.04 million, a price-to-earnings ratio of -4.14 and a beta of 1.88. Cogent Biosciences has a 1 year low of $3.72 and a 1 year high of $12.61.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last released its earnings results on Tuesday, May 6th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.04.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Strs Ohio purchased a new position in shares of Cogent Biosciences during the 1st quarter valued at approximately $36,000. CWM LLC grew its position in Cogent Biosciences by 11,869.9% during the first quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in Cogent Biosciences during the fourth quarter valued at $78,000. Hsbc Holdings PLC purchased a new position in Cogent Biosciences in the fourth quarter valued at $81,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Cogent Biosciences in the fourth quarter worth about $88,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.